Our model suggests a possible role of mitochondrial dysfunction/stress and the rewiring of mitochondrial energy hemostasis (a well-known hallmark of cancer cells) [23] in the emergence of BRAF inhibitor resistance in melanoma. This evidence concerns the gene BRAF and cancer.